

EUROPASS CURRICULUM VITAE



PERSONAL INFORMATION

First name/Surname

Address

Telephone

Fax

E-mail

TAX CODE

Nationality

Date of birth

Place of birth

ORCID ID

WORK EXPERIENCE

• Dates (from - to)

• Name and address of employer

• Type of business or sector

• Occupation or position held

• Dates (from - to)

• Name and address of employer

• Type of business or sector

• Occupation or position held

• Dates (from - to)

Name and address of employer

• Type of business or sector

• Occupation or position held

Occupation or position held

• Dates (from - to)

• Name and address of employer

• Type of business or sector

• Occupation or position held

Dates (from - to)

RENATA GRIFANTINI

- INGM ISTITUTO NAZIONALE GENETICA MOLECOLARE "ROMEO ED ENRICA INVERNIZZI"
- CHECKMAB S.R.L.

PADIGLIONE "ROMEO ED ENRICA INVERNIZZI" - VIA FRANCESCO SFORZA, 35 – 20122 MILANO

02 0066 0220, cell phone +39 333 5687020

02 0066 0216

grifantini@ingm.org; renata.grifantini@checkmab.eu

GRFRM62T59B474P

Italian

19.12.1962

CAMERINO (MC)

[HTTPS://ORCID.ORG/0000-0003-0024-3355](https://orcid.org/0000-0003-0024-3355)

April 2018 - present

CheckmAb S.r.l. – Registered Office: Viale Luigi Majno 26 – Milan; operational headquarters: Via Francesco Sforza n. 35, Padiglione Romeo ed Enrica Invernizzi - Milan

Italian biotech Company for validation of novel therapeutic targets over-expressed in intra-tumoral lymphocytes and specific monoclonal antibodies for cancer immunotherapy.

Chief Scientific Officer and General Director

June 2016 - present

Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi"

Via Francesco Sforza n. 35 – 20122 Milano

Istituto di ricerca scientifica

Head of Translational Research Unit - Discovery and characterization of novel markers and potential targets for autoimmune diseases and cancer, and the development of monoclonal antibodies for immunotherapy

October 2008-May 2016

Externautics SpA

Italian biotech Company, Siena.

Discovery and validation of novel cancer biomarkers, therapeutic targets and monoclonal antibodies for cancer diagnosis and therapy using a "Reverse-Proteomics" approach. Two novel targets and related antibodies were validated for colon cancer, breast and ovary cancer, under outlicencing negotiations.

Research Director

2004-2008

Novartis Vaccines (formerly Chiron Vaccines) - Siena, Italy

Research Center

Project Leader and Head Microarray Unit. Development of Vaccines against different bacterial pathogens. Characterization of bacterial antigen candidates (*Chlamydia trachomatis*, *Yersinia pestis*, *Group B streptococcus*, *Group A streptococcus*, *Neisseria meningitidis*)

April 1998-2004

- Name and address of employer
 - Type of business or sector
 - Occupation or position held

- Dates (from - to)

- Name and address of employer
 - Type of business or sector
 - Occupation or position held

AWARDS AND ACKNOWLEDGMENTS

- Dates (from-to)

Chiron Vaccines – Siena, Italy
 Biochemistry and Molecular Biology Unit
 Senior Scientist - Development of DNA vaccines for malaria, cancer and dust-allergy

April 1990-1996

ENI Research – Milan, Italy
 Biotechnology Department of ENI centralized research Company
 Staff Scientist - Stabilization and optimization of pharmacologically active proteins for industrial production of antibiotics.

2022

“EIC Accelerator Seal of Excellence (to CheckmAb)

2017

“Grant for innovation in Oncology” awarded by Merck Group

1986 Degree award assigned by Foundation “Marsili Feliciangieli”

1981

“Alfieri del Lavoro” Award, assigned by the National Federation of “Cavalieri del lavoro”, consists of the medal of the President of the Republic and is intended for the 25 best students of the year who have completed upper secondary education with full marks.

EDUCATION AND TRAINING

- Dates (from - to)

- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from - to)

- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from - to)

- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

- Dates (from - to))

- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded

2011-2014

University of Bologna - Italy

Characterization of novel cancer targets and therapeutic monoclonal antibodies.

PhD Molecular and Cellular Biology

1989

University of Perugia – Italy (Supervisor: Giuseppe Pelicci)

Identification of novel oncogenes by molecular and cellular biology.

Research Fellow

1988

National Institute of Research (CNR), Rome, Italy (Supervisor: Glauco Tocchini Valentini).

Regulation of RNA processing in *Xenopus laevis*

Research Fellow

1987

University of Camerino (MC) - Italy

Bioengineering of *Spirulina platensis* proteins for nutritional applications (Supervisor: Prof Claudio Orlando Gualerzi)

Research Fellow

- Dates (from - to)

1987

- Name and type of organisation providing education and training
 - Title of qualification awarded
- Dates (from - to)
- Name and type of organisation providing education and training
 - Title of qualification awarded
- Dates (from - to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
 - Title of qualification awarded
- Dates (from - to)
- Name and type of organisation providing education and training
 - Title of qualification awarded

University of Camerino (MC) - Italy
 Professional Certification in Biology. Final mark: 40/40
 1986
 University of Camerino (MC), Italy.
 Doctoral Degree in Biology – Final mark: 110/110 cum laude
 1985 - 1986
Max Planck Institute, Berlin, Germany
 Regulation of protein translation in *E.coli*
 Visiting Scientist
 1977-1982
 Liceo Classico "Antinori", Camerino (MC), Italy
 High School Diploma in classic studies. Final mark 60/60

PERSONAL SKILLS AND COMPETENCES

Long term experience as research director / project leader in biotechnology and big pharmaceutical companies, mainly in charge for applied and translational research in the biomedical and biotechnology fields.
 Attitude for industrial exploitation of scientific achievements and business aspects.
 Competence in Intellectual Property Right strategies.
 Competence and expertise in different areas, including cancer markers, monoclonal antibodies, vaccines, biotechnology, molecular and cellular biology, biochemistry, microbiology, microbial pathogenesis, molecular microbiology, genomic and proteomic technologies, basic molecular oncology, basic immunology,
 Coordinator and Principal Investigator of publicly funded projects
 Supervisor of Master degree, PhD students and Post-Docs

ITALIAN

MOTHER TONGUE

OTHER LANGUAGES

Self Assessment

English

French

	Understanding		Speaking		Writing
	Listening	Reading	Interaction	Production	
English	Fluent	Fluent	Fluent	Fluent	Fluent
French	Scholar	Scholar	Scholar	Scholar	Scholar

ADDITIONAL INFORMATION:

- ✓ 2023-
Member of the Scientific Advisory Board, T-One Therapeutics
- ✓ 2022-
Lead editor of topic "Anti-Tumor Immune Responses" MDPI
- ✓ 2021- present
Review Editor, Translational Medicine, Frontiers
- Member of the Technical Health Commission, Ministry of Health, Biotechnology section,
✓ 2020- present
Scientific Advisor, Achilles Vaccines, Siena (Italy)
- ✓ 2017-present
National Interuniversity Consortium of Materials Science and Technology -Affiliate
- ✓ 2016-present
Scientific Expert OBPA, Fondazione Toscanalifesciences
- ✓ 2009 – present
Expert reviewer of National and European funding programs: POR-FESR, EU-FP7/Horizon 2020, FET-OPEN, Eureka-Eurostars, Innovation Fund Denmark, EISMEA-EIC innovation, EISMEA- EIC TRANSITION, La Caxia foundation, OPJAK.cz, and other national agencies

Selected peer-reviewed publications:

- ✓ SARS-COV-2 specific t-cells in patients with thyroid disorders related to COVID-19 are enriched in the thyroid and acquire a tissue-resident memory phenotype. Silvestri Y, Clemente F, Moschetti G, Maioli S, Carelli E, Espadas de Arias A, Torelli R, Longhi E, De Feo T, Crosti M, Sarnicola ML, Salvi M, Mantovani G, Arosio M, Bombaci M, Pesce E, Grifantini R, Abrignani S, Geginat J, Muller I. Clin Immunol. 2023 Sep;254:109684. doi: 10.1016/j.clim.2023.109684.
- ✓ TMEM123 a key player in immune surveillance of colorectal cancer" Pesce E.* , Cordiglieri C*, Bombaci M, Eppenberger-Castori S, Oliveto S, Manara C, Crosti M, Ercan C, Coto Llerena M, Gobbi A, Campagnoli S, Donnarumma T, Martinelli M, Bevilacqua V, De Camilli E, Guarini P, Sarnicola ML, Cassinotti E, Baldari L, Giuseppe Viale, Biffo S, Abrignani A, Terracciano LM* and R Grifantini R* Front Immunol. 2023 Jun 23;14:1194087. doi: 10.3389/fimmu.2023.1194087.
- ✓ Comments on "PD-1 Inhibitor for Disseminated Mycobacterium avium Infection in a Person Living With HIV". Lombardi A, Gramaglia A, Guarini P, Grifantini R, Gori A, Blasi F, Bandera A. Open Forum Infect Dis. 2023 Feb 14;10(3):ofad083. doi: 10.1093/ofid/ofad083.
- ✓ Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation. Pagani L, Chinello C, Risca G, Capitoli G, Criscuolo L, Lombardi A, Ungaro R, Mangioni D, Piga I, Muscatello A, Blasi F, Favalli A, Martinovic M, Gori A, Bandera A, Grifantini R*, Magni F*. Int J Mol Sci. 2023 Feb 10;24(4):3570. doi: 10.3390/ijms24043570.
- ✓ Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. Miluzio A, Cuomo A, Cordiglieri C, Donnici L, Pesce E, Bombaci M, Conti M, Fasciani A, Terracciano L, Manganaro L, Toccafondi M, Scagliola A, Oliveto S, Ricciardi S, Grifantini R, De Francesco R, Abrignani S, Manfrini N, Biffo S. EBioMedicine. 2023 Jan;87:104390. doi: 10.1016/j.ebiom.2022.104390.
- ✓ SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Bowen JE, Park YJ, Stewart C, Brown JT, Sharkey WK, Walls AC, Joshi A, Sprouse KR, McCallum M, Tortorici MA, Franko NM, Logue JK, Mazzitelli IG, Nguyen AW, Silva RP, Huang Y, Low JS, Jerak J, Tiles SW, Ahmed K, Shariq A, Dan JM, Zhang Z, Weiskopf D, Sette A, Snell G, Posavad CM, Iqbal NT, Geffner J, Bandera A, Gori A, Sallusto F, Maynard JA, Crotty S, Van

- Voorhis WC, Simmerling C, Grifantini R, Chu HY, Corti D, Veessler D. *Sci Immunol*. 2022 Nov 10:eadf1421. doi: 10.1126/sciimmunol.adf1421.
- ✓ Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Fedele G, Trentini F, Schiavoni I, Abrignani S, Antonelli G, Baldo V, Baldovin T, Bandera A, Bonura F, Clerici P, De Paschale M, Fortunato F, Gori A, Grifantini R, Icardi G, Lazzarotto T, Lodi V, Mastroianni CM, Orsi A, Prato R, Restivo V, Carsetti R, Piano Mortari E, Leone P, Olivetta E, Fiore S, Di Martino A, Brusaferrero S, Merler S, Palamara AT, Stefanelli P. *Front Immunol*. 2022. doi: 10.3389/fimmu.2022.1021396..
 - ✓ Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers. Borghi MO, Bombaci M, Bodio C, Lonati PA, Gobbini A, Lorenzo M, Torresani E, Dubini A, Bulgarelli I, Solari F, Pregnolato F, Bandera A, Gori A, Parati G, Abrignani S, Grifantini R*, Meroni PL. *Front Immunol*. 2022 Jul 15;13:930074. doi: 10.3389/fimmu.2022.930074. eCollection 2022.
 - ✓ Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Bowen JE, Addetia A, Dang HV, Stewart C, Brown JT, Sharkey WK, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Franko NM, Czudnochowski N, Powell AE, Dellota E Jr, Ahmed K, Ansari AS, Cameroni E, Gori A, Bandera A, Posavad CM, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Iqbal NT, Corti D, Geffner J, Snell G, Grifantini R, Chu HY, Veessler D. *Science*. 2022 Aug 19;377(6608):890-894. doi: 10.1126/science.abq0203. Epub 2022 Jul 19.
 - ✓ Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. Favalli A, Favalli EG, Gobbini A, Zagato E, Bombaci M, Maioli G, Pesce E, Donnici L, Gruarin P, Biggioggero M, Curti S, Manganaro L, Marchisio E, Bevilacqua V, Martinovic M, Fabbris T, Sarnicola ML, Crosti M, Marongiu L, Granucci F, Notarbartolo S, Bandera A, Gori A, De Francesco R, Abrignani S, Caporali R, Grifantini R*. *Front Immunol*. 2022 Jun 10;13:873195. doi: 10.3389/fimmu.2022.873195. eCollection 2022.
 - ✓ Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2. Francesconi O, Donnici L, Fragai M, Pesce E, Bombaci M, Fasciani A, Manganaro L, Conti M, Grifantini R*, De Francesco R, Nativi C, Roelens S. *iScience*. 2022 May 20;25(5):104239. doi: 10.1016/j.isci.2022.104239. Epub 2022 Apr 11.
 - ✓ The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandera A, Gori A, Abrignani S, Grifantini R*, Caporali R. *Front Med (Lausanne)*. 2022 Mar 11;9:850858. doi: 10.3389/fmed.2022.850858. eCollection 2022.
 - ✓ Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination. Lonati PA, Bodio C, Scavone M, Martini G, Pesce E, Bandera A, Lombardi A, Gerosa M, Franceschini F, Tincani A, Podda G, Abrignani S, Grifantini R, Cattaneo M, Borghi MO, Meroni PL. *RMD Open*. 2022 Feb;8(1):e001902. doi: 10.1136/rmdopen-2021-001902.
 - ✓ Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response. Pesce E, Manfrini N, Cordiglieri C, Santi S, Bandera A, Gobbini A, Gruarin P, Favalli A, Bombaci M, Cuomo A, Collino F, Cricri G, Ungaro R, Lombardi A, Mangioni D, Muscatello A, Aliberti S, Blasi F, Gori A, Abrignani S, De Francesco R, Biffo S, Grifantini R*. *Front Immunol*. 2022 Jan 17;12:785941. doi: 10.3389/fimmu.2021.785941. eCollection 2021.
 - ✓ Pagani, L.; Chinello, C.; Mahajneh, A.; Clerici, F.; Criscuolo, L.; Favalli, A.; Gruarin, P.; Grifantini, R.; Bandera, A.; Lombardi, A.; Ungaro, R.; Muscatello, A.; Blasi, F.; Gori, A.; Magni, F. Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome. *BioChem* 2022, 2, 64-82.

- ✓ Elucidating the 3D Structure of a Surface Membrane Antigen from *Trypanosoma cruzi* as a Serodiagnostic Biomarker of Chagas Disease. Di Pisa F, De Benedetti S, Fassi EMA, Bombaci M, Grifantini R, Musicò A, Frigerio R, Pontillo A, Rigo C, Abelli S, Grande R, Zanchetta N, Mileto D, Mancon A, Rizzo A, Gori A, Cretich M, Colombo G, Bolognesi M, Gourlay LJ. *Vaccines (Basel)*. 2022 Jan 3;10(1):71. doi: 10.3390/vaccines10010071.
- ✓ LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion. Marasca F, Sinha S, Vadalà R, Polimeni B, Ranzani V, Paraboschi EM, Burattin FV, Ghilotti M, Crosti M, Negri ML, Campagnoli S, Notarbartolo S, Sartore-Bianchi A, Siena S, Prati D, Montini G, Viale G, Torre O, Harari S, Grifantini R, Soldà G, Biffo S, Abrignani S, Bodega B. *Nat Genet*. 2022 Feb;54(2):180-193. doi: 10.1038/s41588-021-00989-7. Epub 2022 Jan 17.
- ✓ Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. Amatu A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, Cassingena A, Tosi F, Ghezzi S, Campisi D, Grifantini R, Abrignani S, Siena S, Scaglione F, Sartore-Bianchi A. *Eur J Cancer*. 2022 Mar;163:16-25. doi: 10.1016/j.ejca.2021.12.006. Epub 2021 Dec 22.
- ✓ Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà PE, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Snell G, Veessler D, Corti D. *Nature*. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
- ✓ SARS-CoV-2 spike conformation determines plasma neutralizing activity. Bowen JE, Walls AC, Joshi A, Sprouse KR, Stewart C, Tortorici MA, Franko NM, Logue JK, Mazzitelli IG, Tiles SW, Ahmed K, Shariq A, Snell G, Iqbal NT, Geffner J, Bandera A, Gori A, Grifantini R, Chu HY, Van Voorhis WC, Corti D, Veessler D. *bioRxiv*. 2021 Dec 21:2021.12.19.473391. doi: 10.1101/2021.12.19.473391.
- ✓ Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study. Lombardi A, Butta GM, Donnici L, Bozzi G, Oggioni M, Bono P, Matera M, Consonni D, Ludovisi S, Muscatello A, Ceriotti F, Conti M, Scaglioni S, Gallo G, Scarpa E, Letko M, Abrignani S, Grifantini R, De Francesco R, Gori A, Manganaro L, Bandera A. *Lancet Reg Health Eur*. 2022 Feb;13:100287. doi: 10.1016/j.lanepe.2021.100287. Epub 2021 Dec 23.
- ✓ Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, VanBlargan LA, De Marco A, Zepeda SK, Iulio JD, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà P, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Veessler D, Snell G, Corti D. *bioRxiv*. 2021 Dec 20:2021.12.12.472269. doi: 10.1101/2021.12.12.472269.
- ✓ Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, Gobbini A, Galeota E, Manara C, Bombaci M, Pesce E, Zagato E, Favalli A, Sarnicola ML, Curti S, Crosti M, Martinovic M, Fabbris T, Marini F, Donnici L, Lorenzo M, Mancino M, Ungaro R, Lombardi A, Mangioni D, Muscatello A, Aliberti S, Blasi F, De Feo T, Prati D, Manganaro L, Granucci F, Lanzavecchia A, De Francesco R, Gori A, Grifantini R*,

- Abrignani S. *Sci Immunol*. 2021 Aug 10;6(62):eabg5021. doi: 10.1126/sciimmunol.abg5021.
- ✓ Structure, Immunoreactivity, and In Silico Epitope Determination of SmSPI S. mansonii Serpin for Immunodiagnostic Application. De Benedetti S, Di Pisa F, Fassi EMA, Cretich M, Musicò A, Frigerio R, Mussida A, Bombaci M, Grifantini R, Colombo G, Bolognesi M, Grande R, Zanchetta N, Gismondo MR, Mileto D, Mancon A, Gourlay LJ. *Vaccines (Basel)*. 2021 Apr 1;9(4):322. doi: 10.3390/vaccines9040322. PMID: 33915716
 - ✓ A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer. Amedei A, Asadzadeh F, Papi F, Vannucchi MG, Ferrucci V, Bermejo IA, Fragai M, De Almeida CV, Cerofolini L, Giuntini S, Bombaci M, Pesce E, Niccolai E, Natali F, Guarini E, Gabel F, Traini C, Catarinichia S, Ricci F, Orzalesi L, Berti F, Corzana F, Zollo M, Grifantini R*, Nativi C. *iScience*. 2020 Jun 26;23(6):101250. doi: 10.1016/j.isci.2020.101250. Epub 2020 Jun 6. PMID: 32629615
 - ✓ Discovery and Preliminary Characterization of Translational Modulators that Impair the Binding of eIF6 to 60S Ribosomal Subunits. Pesce E, Miluzio A, Turcano L, Minici C, Cirino D, Calamita P, Manfrini N, Oliveto S, Ricciardi S, Grifantini R, Degano M, Bresciani A, Biffo S. *Cells*. 2020 Jan 10;9(1):172. doi: 10.3390/cells9010172. PMID: 31936702
 - ✓ Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. Bombaci M, Pesce E, Torri A, Carpi D, Crosti M, Lanzafame M, Cordiglieri C, Sinisi A, Moro M, Bernuzzi F, Gerussi A, Geginat J, Muratori L, Terracciano LM, Invernizzi P, Abrignani S, Grifantini R*. *Liver Int*. 2019 Nov;39(11):2124-2135. doi: 10.1111/liv.14128. Epub 2019 May 15. PMID: 31033124
 - ✓ Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. Grifantini R, Taranta M, Gherardini L, Naldi I, Parri M, Grandi A, Giannetti A, Tombelli S, Lucarini G, Ricotti L, Campagnoli S, De Camilli E, Pelosi G, Baldini F, Menciasci A, Viale G, Pileri P, Cinti C. *J Control Release*. 2018 Jun 28;280:76-86. doi: 10.1016/j.jconrel.2018.04.052. Epub 2018 May 4. PMID: 29733876
 - ✓ Enhancing Antibody Serodiagnosis Using a Controlled Peptide Coimmobilization Strategy. Sola L, Gagni P, D'Annessa I, Capelli R, Bertino C, Romanato A, Damin F, Bergamaschi G, Marchisio E, Cuzzocrea A, Bombaci M, Grifantini R, Chiari M, Colombo G, Gori A, Cretich M. *ACS Infect Dis*. 2018 Jun 8;4(6):998-1006. doi: 10.1021/acsinfectdis.8b00014. Epub 2018 Mar 29. PMID: 29570266
 - ✓ Big data: challenge and opportunity for translational and industrial research in healthcare. RL Rossi and Grifantini R*. *Frontiers in Digital humanities*, 2018 <https://doi.org/10.3389/fdigh.2018.00013>
 - ✓ TCTN2: a novel tumor marker with oncogenic properties. Cano-Rodriguez D, Campagnoli S, Grandi A, Parri M, Camilli E, Song C, Jin B, Lacombe A, Pierleoni A, Bombaci M, Cordiglieri C, Ruiters MH, Viale G, Terracciano L, Sarmientos P, Abrignani S, Grandi G, Pileri P, Rots MG, Grifantini R*. *Oncotarget*. 2017 Aug 24;8(56):95256-95269. doi: 10.18632/oncotarget.20438. eCollection 2017 Nov 10. PMID: 29221125
 - ✓ CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. *Sci Rep*. 2017 Mar 30;7:45477. doi: 10.1038/srep45477. PMID: 28358118
 - ✓ Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs" [*Biomaterials* 76C (2015) 399-407]. Fan L, Zhang Y, Wang F, Yang Q, Tan J, Grifantini R, Wu H, Song C, Jin B. *Biomaterials*. 2017 Apr;122:201. doi: 10.1016/j.biomaterials.2016.11.002. Epub 2016 Dec 18. PMID: 28003046 No abstract available.
 - ✓ ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. Grandi A, Santi A, Campagnoli S, Parri M, De Camilli E, Song C, Jin B, Lacombe A, Castori-Eppenberger S, Sarmientos P, Grandi G, Viale G, Terracciano L, Chiarugi P, Pileri P, Grifantini R*. *Oncotarget*. 2016 Sep

27;7(39):63596-63610. doi: 10.18632/oncotarget.11550. PMID: 27566589

- ✓ FAT1: a potential target for monoclonal antibody therapy in colon cancer. Pileri P, Campagnoli S, Grandi A, Parri M, De Camilli E, Song C, Ganfini L, Lacombe A, Naldi I, Sarmientos P, Cinti C, Jin B, Grandi G, Viale G, Terracciano L, Grifantini R*. *Br J Cancer*. 2016 Jun 28;115(1):40-51. doi: 10.1038/bjc.2016.145. Epub 2016 Jun 21. PMID: 27328312
- ✓ Supporting Data for Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs. Wu G, Song C, Grifantini R, Fan L, Wu H, Jin B. *Data Brief*. 2016 Feb 15;7:148-51. doi: 10.1016/j.dib.2016.02.026. eCollection 2016 Jun. PMID: 26933672.
- ✓ Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting. Fan L, Campagnoli S, Wu H, Grandi A, Parri M, De Camilli E, Grandi G, Viale G, Pileri P, Grifantini R, Song C, Jin B. *J Exp Clin Cancer Res*. 2015 Sep 15;34(1):103. doi: 10.1186/s13046-015-0214-x. PMID: 26373379
- ✓ Angiopoietin-like 7, a novel pro-angiogenic factor over-expressed in cancer. Parri M, Pietrovito L, Grandi A, Campagnoli S, De Camilli E, Bianchini F, Marchiò S, Bussolino F, Jin B, Sarmientos P, Grandi G, Viale G, Pileri P, Chiarugi P, Grifantini R*. *Angiogenesis*. 2014 Oct;17(4):881-96. doi: 10.1007/s10456-014-9435-4. Epub 2014 Jun 6. PMID: 24903490
- ✓ Recombinant outer membrane vesicles carrying *Chlamydia muridarum* HtrA induce antibodies that neutralize chlamydial infection in vitro. Bartolini E, Ianni E, Frigimelica E, Petracca R, Galli G, Berlanda Scorza F, Norais N, Laera D, Giusti F, Pierleoni A, Donati M, Cevenini R, Finco O, Grandi G, Grifantini R. *J Extracell Vesicles*. 2013 May 6;2. doi: 10.3402/jev.v2i0.20181. eCollection 2013. PMID: 24009891
- ✓ Adaptive response of Group B streptococcus to high glucose conditions: new insights on the CovRS regulation network. Di Palo B, Rippa V, Santi I, Brettoni C, Muzzi A, Metruccio MM, Grifantini R, Telford JL, Paccani SR, Soriani M. *PLoS One*. 2013 Apr 9;8(4):e61294. doi: 10.1371/journal.pone.0061294. Print 2013. PMID: 23585887
- ✓ EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts. Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R, Fibbi G, Mazzanti B, Calorini L, Chiarugi P. *J Mol Med (Berl)*. 2013 Jan;91(1):103-15. doi: 10.1007/s00109-012-0941-9. Epub 2012 Aug 19. PMID: 22903544
- ✓ Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M, Capo S, Falugi F, Manetti AG, Donato P, Swennen E, Gallotta M, Garibaldi M, Pinto V, Chiappini N, Musser JM, Janulczyk R, Mariani M, Scarselli M, Telford JL, Grifantini R, Norais N, Margarit I, Grandi G. *Mol Cell Proteomics*. 2012 Jun;11(6):M111.015693. doi: 10.1074/mcp.M111.015693. Epub 2012 Jan 27. PMID: 22286755
- ✓ Surface interactome in *Streptococcus pyogenes*. Galeotti CL, Bove E, Pezzicoli A, Nogarotto R, Norais N, Pileri S, Lelli B, Falugi F, Balloni S, Tedde V, Chiarot E, Bombaci M, Soriani M, Bracci L, Grandi G, Grifantini R. *Mol Cell Proteomics*. 2012 Apr;11(4):M111.015206. doi: 10.1074/mcp.M111.015206. Epub 2011 Dec 22. PMID: 22199230
- ✓ Peroxide stimulon and role of PerR in group A Streptococcus. Grifantini R, Toukoki C, Colaprico A, Gryllos I. *J Bacteriol*. 2011 Dec;193(23):6539-51. doi: 10.1128/JB.05924-11. Epub 2011 Sep 23. PMID: 21949080
- ✓ A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. Grifantini R*, Pagani M, Pierleoni A, Grandi A, Parri M, Campagnoli S, Pileri P, Cattaneo D, Canidio E, Pontillo A, De Camilli E, Bresciani A, Marinoni F, Pedrazzoli E, Nogarotto R, Abrignani S, Viale G, Sarmientos P, Grandi G. *J Proteomics*. 2011 Dec 21;75(2):532-47. doi:

10.1016/j.jprot.2011.08.018. Epub 2011 Sep 5. PMID: 21920474

- ✓ Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E, Meoni E, Bonci A, Agnusdei M, Nardelli F, Bartolini E, Scarselli M, Caproni E, Laera D, Zedda L, Skibinski D, Giovinazzi S, Bastone R, Ianni E, Cevenini R, Grandi G, Grifantini R. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9969-74. doi: 10.1073/pnas.1101756108. Epub 2011 May 31. PMID: 21628568
- ✓ Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. Soriani M, Petit P, Grifantini R, Petracca R, Gancitano G, Frigimelica E, Nardelli F, Garcia C, Spinelli S, Scarabelli G, Fiorucci S, Affentranger R, Ferrer-Navarro M, Zacharias M, Colombo G, Vuillard L, Daura X, Grandi G. J Biol Chem. 2010 Sep 24;285(39):30126-38. doi: 10.1074/jbc.M110.118513. Epub 2010 Jun 30. PMID: 20592031
- ✓ Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. Bombaci M, Grifantini R, Mora M, Reguzzi V, Petracca R, Meoni E, Balloni S, Zingaretti C, Falugi F, Manetti AG, Margarit I, Musser JM, Cardona F, Orefici G, Grandi G, Bensi G. PLoS One. 2009 Jul 22;4(7):e6332. doi: 10.1371/journal.pone.0006332. PMID: 19623252
- ✓ CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S, Bonci A, Petracca R, Bartolini E, Galli G, Agnusdei M, Nardelli F, Buricchi F, Norais N, Ferlenghi I, Donati M, Cevenini R, Finco O, Grandi G, Grifantini R. Infect Immun. 2009 Sep;77(9):4168-76. doi: 10.1128/IAI.00344-09. Epub 2009 Jul 13. PMID: 19596772
- ✓ CsrRS regulates group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine development. Santi I, Grifantini R, Jiang SM, Brettoni C, Grandi G, Wessels MR, Soriani M. J Bacteriol. 2009 Sep;191(17):5387-97. doi: 10.1128/JB.00370-09. Epub 2009 Jun 19. PMID: 19542277
- ✓ Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. Margarit I, Bonacci S, Pietrocola G, Rindi S, Ghezzi C, Bombaci M, Nardi-Dei V, Grifantini R, Speciale P, Grandi G. FASEB J. 2009 Sep;23(9):3100-12. doi: 10.1096/fj.09-131458. Epub 2009 May 5. PMID: 19417080
- ✓ PerR confers phagocytic killing resistance and allows pharyngeal colonization by group A Streptococcus. Gryllos I, Grifantini R, Colaprico A, Cary ME, Hakansson A, Carey DW, Suarez-Chavez M, Kalish LA, Mitchell PD, White GL, Wessels MR. PLoS Pathog. 2008 Sep 5;4(9):e1000145. doi: 10.1371/journal.ppat.1000145. PMID: 18773116
- ✓ Identification of 2 hypothetical genes involved in Neisseria meningitidis cathelicidin resistance. Frigimelica E, Bartolini E, Galli G, Grandi G, Grifantini R. J Infect Dis. 2008 Apr 15;197(8):1124-32. doi: 10.1086/533456. PMID: 18462162
- ✓ Mg(2+) signalling defines the group A streptococcal CsrRS (CovRS) regulon. Gryllos I, Grifantini R, Colaprico A, Jiang S, Deforce E, Hakansson A, Telford JL, Grandi G, Wessels MR. Mol Microbiol. 2007 Aug;65(3):671-83. doi: 10.1111/j.1365-2958.2007.05818.x. Epub 2007 Jul 3. PMID: 17608796
- ✓ Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Hotopp JCD, Grifantini R, Kumar N, Tzeng YL, Fouts D, Frigimelica E, Draghi M, Giuliani MM, Rappuoli R, Stephens DS, Grandi G, Tettelin H. Microbiology (Reading). 2006 Dec;152(Pt 12):3733-3749. doi: 10.1099/mic.0.29261-0. PMID: 17159225
- ✓ Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Bartolini E, Frigimelica E, Giovinazzi S, Galli G, Shaik Y, Genco C, Welsch JA, Granoff DM, Grandi G, Grifantini R. Mol Microbiol. 2006 May;60(4):963-72. doi: 10.1111/j.1365-2958.2006.05163.x.PMID: 16677307

- ✓ Effect of *Neisseria meningitidis* fur mutations on global control of gene transcription. Delany I, Grifantini R, Bartolini E, Rappuoli R, Scarlato V. *J Bacteriol.* 2006 Apr;188(7):2483-92. doi: 10.1128/JB.188.7.2483-2492.2006. PMID: 16547035
- ✓ Characterization of a novel *Neisseria meningitidis* Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Grifantini R, Frigimelica E, Delany I, Bartolini E, Giovinnazzi S, Balloni S, Agarwal S, Galli G, Genco C, Grandi G. *Mol Microbiol.* 2004 Nov;54(4):962-79. doi: 10.1111/j.1365-2958.2004.04315.x. PMID: 15522080
- ✓ Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of *Neisseria meningitidis* group B. Grifantini R, Sebastian S, Frigimelica E, Draghi M, Bartolini E, Muzzi A, Rappuoli R, Grandi G, Genco CA. *Proc Natl Acad Sci U S A.* 2003 Aug 5;100(16):9542-7. doi: 10.1073/pnas.1033001100. Epub 2003 Jul 25. PMID: 12883001
- ✓ Gene expression profile in *Neisseria meningitidis* and *Neisseria lactamica* upon host-cell contact: from basic research to vaccine development. Grifantini R, Bartolini E, Muzzi A, Draghi M, Frigimelica E, Berger J, Randazzo F, Grandi G. *Ann N Y Acad Sci.* 2002 Dec;975:202-16. doi: 10.1111/j.1749-6632.2002.tb05953.x. PMID: 12538166
- ✓ Different profile of CD8+ effector T cells induced in Der p 1-allergic and naïve mice by DNA vaccination. Draghi M, Jarman ER, Grifantini R, Galli-Stampino L, Lamb JR, Valiante NM, Grandi G. *Eur J Immunol.* 2002 Dec;32(12):3720-8. doi: 10.1002/1521-4141(200212)32:12<3720::AID-IMMU3720>3.0.CO;2-J. PMID: 12516566
- ✓ Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Grifantini R, Bartolini E, Muzzi A, Draghi M, Frigimelica E, Berger J, Ratti G, Petracca R, Galli G, Agnusdei M, Giuliani MM, Santini L, Brunelli B, Tettelin H, Rappuoli R, Randazzo F, Grandi G. *Nat Biotechnol.* 2002 Sep;20(9):914-21. doi: 10.1038/nbt728. Epub 2002 Aug 12. PMID: 12172557
- ✓ Combined automated PCR cloning, in vitro transcription/translation and two-dimensional electrophoresis for bacterial proteome analysis. Norais N, Nogarotto R, Lacobini ET, Garaguso I, Grifantini R, Gauli G, Grandi G. *Proteomics.* 2001 Nov;1(11):1378-89. doi: 10.1002/1615-9861(200111)1:11<1378::AID-PROT1378>3.0.CO;2-S. PMID: 11922598
- ✓ Emulsion/solvent evaporation as an alternative technique in pellet preparation. Palmieri GF, Grifantini R, Di Martino P, Martelli S. *Drug Dev Ind Pharm.* 2000 Nov;26(11):1151-8. doi: 10.1081/ddc-100100986. PMID: 11068688
- ✓ Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kocken C, Thomas A, Abrignani S, Grandi G. *Eur J Immunol.* 1998 Apr;28(4):1225-32. doi: 10.1002/(SICI)1521-4141(199804)28:04<1225::AID-IMMU1225>3.0.CO;2-6. PMID: 9565362
- ✓ Efficient conversion of 5-substituted hydantoins to D-alpha-amino acids using recombinant *Escherichia coli* strains. Grifantini R, Galli G, Carpani G, Pratesi C, Frascotti G, Grandi G. *Microbiology (Reading).* 1998 Apr;144 (Pt 4):947-954. doi: 10.1099/00221287-144-4-947. PMID: 9579068
- ✓ Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II. Ruggiero P, Bossù P, Macchia G, Del Grosso E, Sabbatini V, Bertini R, Colagrande A, Bizzarri C, Maurizi G, Di Cioccio V, D'Andrea G, Di Giulio A, Frigerio F, Grifantini R, Grandi G, Tagliabue A, Boraschi D. *J Immunol.* 1997 Apr 15;158(8):3881-7. PMID: 9103457
- ✓ Topological mapping of the cysteine residues of N-carbamyl-D-amino-acid amidohydrolase and their role in enzymatic activity. Grifantini R, Pratesi C, Galli G, Grandi G. *J Biol Chem.* 1996 Apr 19;271(16):9326-31. doi: 10.1074/jbc.271.16.9326. PMID: 8621596
- ✓ Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like

domains. Boraschi D, Bossù P, Ruggiero P, Tagliabue A, Bertini R, Macchia G, Gasbarro C, Pellegrini L, Melillo G, Ulisse E, Visconti U, Bizzarri C, Del Grosso E, Mackay AR, Frascotti G, Frigerio F, Grifantini R, Grandi G. *J Immunol.* 1995 Nov 15;155(10):4719-25. PMID: 7594472

- ✓ Production and regeneration of spheroplasts from the cyanobacterium *Spirulina platensis*. L. Lanfaroni, R. Grifantini, A. Petris, and Gualerzi CO. *FEMS Microbiology Letters*, Volume 59, Issue 1-2, May 1989, Pages 141–146, <https://doi.org/10.1111/j.1574-6968.1989.tb03098.x>

Book Chapters

- ✓ Bombaci M and Grifantini R. (2010) Protein microarrays applications in biological and medical research” in *New Research Trends in Protein Chip Technology*, Edited by S. Carnazza
- ✓ Grifantini R and Grandi G., *Chlamydia trachomatis vaccines* (2010), *New generation Vaccines*, 4th edition, Edited by M.M. Levine, Marcel Dekker
- ✓ Grandi G, Margarit I, Frigerio F., Nogarotto R, Carpani G, Grifantini R, G. Galli (2000) Stabilization of Industrial enzymes by protein engineering. In *“Protein Engineering in Industrial Biotechnology”* Lilia Alberghina (ed.) Harwood Academic Publishers, The Netherlands, 147-157
- ✓ Norais N., Nogarotto R., Iacobini E.T., Garaguso I., Grifantini R., Galli G., Grandi G. (2003). Protein identification from 2-D gels using in vitro transcription translation products. In *Handbook of Proteomic Methods*, P. Michael Conn, ed., Totowa, NJ: Human Press.

Funding. Selected major grants in which R.Grifantini was Coordinator PI (*) or co-proponent PI [Funding program, period, net contribution for the beneficiary institution, Title (acronym)]

- ✓ RF-2021- 12372668 Theory enhancing B cells-driven protection against *Klebsiella pneumoniae*: potential for prevention and treatment (KPPROTECT) – ongoing (*)
- ✓ Call COVID19, HUB Por-Fers 20014-2020, 01/05/2020-31/12/2020, 167 k€ Impatto dell’infezione di COVID-19 nelle malattie reumatiche croniche trattate con farmaci immunosoppressori (MAINSTREAM)
- ✓ Call COVID19, HUB Por-Fers 20014-2020, 01/05/2020-31/12/2020, 350 k€ Caratterizzazione della risposta immunitaria protettiva in pazienti affetti da COVID-19 e realizzazione di un saggio immuno-diagnostico (Co-IMMUNITY) (*).
- ✓ Call-HUB Por-Fers 2014-2020, 01/11/2019-31/09/2022, 767 k€ Second generation drugs for cancer immunotherapy (Immun-HUB)
- ✓ Grant for Innovation in Oncology 2017, Merck KGaA, 01/01/2018-30/06/2020, 400 k€, Novel targets of tumor-infiltrating CD4+ regulatory T cells for immunotherapy (*).
- ✓ PorFESR 2014-2020, 09/9/2017-30/06/2021, 694 k€, “Sviluppo di un saggio per la diagnosi precoce di artriti infiammatorie croniche sieronegative “(ArtiDe)
- ✓ Por FESR 2014-2020, 21/82017-31/12/2019, 392 k€, “Network Regionale per lo sviluppo di metodi Diagnostici in risposta rapida a epidemie emergenti e bioemergenze” (READY)
- ✓ Grant4target,BAYER, 01/01/2017-31/12/2017, 40 k€, “Validation of novel potential therapeutic target for pancreas cancer and CRC “(*)
- ✓ POR FESR 2014-2020, 160 k€, “Development of a multifunctional platform for the evaluation of antitumor therapeutic agents and vaccines against human pathogens” (Magic-Theravax)* discontinued due to exit of main SME (*)
- ✓ EU-FP7, Senior ERC 2014, 01/06/2014 –411 k€, “Outer Membrane Vesicles from “Vaccinobacter”: A Synthetic Biology approach for effective vaccines against infectious diseases and cancer”(OMVAC) (Role:PI of the Second Beneficiary Institution of the Grant, awarded to Prof Guido Grandi)

- ✓ EU-FP7, 2013 SME-Targeted Collaborative project, 01/04/2014 – 31/03/2019, 275 k€, Title: "Improving Prostate Cancer Outcome with Vectored Vaccines" (IMPROVE)
- ✓ Eurotransbio 01/10/2009-01/10/2011, 109 k€, "Identification of novel tumor marker for diagnosis and therapy"(ProTuMa)(*)
- ✓ Por CREO 2007-2013, 28/12/2012- 31/03/2015, 801 k€, "New multi-functional technology platform for the immunotherapy of tumors: synergy between adoptive allogeneic cell therapy, monoclonal antibodies and immune-stimulating molecules" (ACTILA)
- ✓ Por CREO 2007-2013, 01/10/2009-31/12/2011, 410 k€, "Novel markers for cancer diagnosis and therapy" (TuMar)(*)

Patents

Inventor of approximately 27 families of patents/patent applications (most issued patents).
(Publication numbers, Title, Current Assignees)

GB2106075.1, filed 28 April 2021 not published yet

US20170227543 A1 Breast Tumor Markers And Methods Of Use Thereof, EXTERNAUTICS

WO200749155 A2 Compositions comprising yersinia pestis antigens, NOVARTIS VACCINES &DIAGNOSTICS

US5877003 A Thermostable Mutants of D-N- .alpha.-carbamoylase ,ENRICERCHE

WO2016184860 A1, Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof,UNIVERSITA DEGLI STUDI DI TRENTO

WO2014198919 A2 Tumor marker, monoclonal antibodies and methods of use thereof,EXTERNAUTICS

AU2013202316 A1 Compositions comprising Yersinia pestis antigens, NOVARTIS VACCINES &DIAGNOSTICS

WO201151271 A2 Prostate tumor markers and methods of use thereof, EXTERNAUTICS

WO201151280 A1 Ovary tumor markers and methods of use thereof, EXTERNAUTICS

WO201151276 A1 Colon and rectal tumor markers and methods of use thereof, EXTERNAUTICS

WO201151277 A1 Breast tumor markers and methods of use thereof, EXTERNAUTICS

WO201151278 A1 Lung tumor markers and methods of use thereof, EXTERNAUTICS

GB201009861 D0 Omv vaccines, GLAXOSMITHKLINE BIOLOGICALS

EP2383578 A1 Tumor marker and methods of use thereof, EXTERNAUTICS

WO2010100632 A2 Chlamydia antigens, GLAXOSMITHKLINEBIOLOGICALS

WO2009109860 A2 Mutant forms of chlamydia HtrA, NOVARTIS

GB200903858 D0 Diagnosis of neuropsychiatric and behavioural disorders, NOVARTIS

EP2214019 A1 Tumor markers and methods of use thereof, EXTERNAUTICS

EP2213686 A1 Tumor markers and methods of use thereof, EXTERNAUTICS

GB200717187 D0 Compositions comprising yersinia pestis antigens, NOVARTIS

IT97MI0475 A1 Mutanti di il-1beta con capacita' selettiva di inibizione di il-1r2, DOMPé

IT96MI0577 D0 Mutanti di il-1beta con capacita' selettiva di inibizione di il-1r2, DOMPé

IT95MI2700 D0 Thermostable mutants of D-N-alpha-Carbamoylase, ENRICERCHE

IT95MI2432 D0 Preparation of D-alpha-amino acids, using bacteria transformed with the carbamoylase-hydantoinase operon, ENITECNOLOGIE

IT95MI0660 D0 Mutanti di il-1beta con capacita' selettiva di inibizione di il-1r2, DOMPE

IT94MI1916 D0 Il-1 receptor antagonists with enhanced inhibitory activity DOMPé FARMACEUTICI,

IT94MI0726 D0 Process for the production of D-alpha-amino acids, ENRICERCHE

IT94MI0725 D0 Stable mutants of D-N-alpha-carbamylase, ENRICERCHE

I, the undersigned, am aware that, pursuant to art. 26 of Law 15/68, false statements, false documents and using false acts are punishable under the Penal Code and special laws. I authorize the processing of personal data contained in my curriculum vitae on the basis of art. 13 of Legislative Decree 196/2003 and art. 13 GDPR (EU Regulation 2016/679).

Milan, 30.09.2023

RENATA GRIFANTINI

